<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02856802</url>
  </required_header>
  <id_info>
    <org_study_id>DFN-02-CD-012</org_study_id>
    <nct_id>NCT02856802</nct_id>
  </id_info>
  <brief_title>An Efficacy and Safety Study of DFN-02</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A safety and efficacy of DFN-02, being conducted at multiple centers in the United States.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 11, 2016</start_date>
  <completion_date type="Actual">October 2017</completion_date>
  <primary_completion_date type="Actual">February 10, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients who are pain-free at 2 hours postdose in the first double-blind treatment period</measure>
    <time_frame>2 days to 28 days, depending on when the first migraine is treated with study drug</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">107</enrollment>
  <condition>Migraine Headaches</condition>
  <arm_group>
    <arm_group_label>DFN-02</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DFN-02 Active</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>DFN-02 Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DFN-02</intervention_name>
    <arm_group_label>DFN-02</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>DFN-02 Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A history of episodic migraine who experience an average of 2 to 8 migraine attacks
             per month for at least the past 12 months, with no more than 14 headache days per
             month, and with 48 hours of headache free time between migraine headaches

          2. Patients who have migraine with or without aura. If migraine with aura, the aura
             cannot last longer than 60 minutes.

          3. Patients who are willing and able to:

               1. Evaluate and record pain, migraine symptoms, and study medication effectiveness
                  information in real-time using an eDiary for the duration of the study;

               2. Record each instance of the use of study medication and rescue medication in a
                  patient eDiary in real-time for the duration of the study;

               3. Comply with all other study procedures and scheduling requirements.

        Exclusion Criteria:

          1. Minors, even if they are in the specified study age range

          2. Medication overuse:

               1. Opioids ≥ 10 days during the 90 days prior to screening

               2. Combination medications (e.g., Fiorinal®) ≥ 10 days during the 90 days prior to
                  screening (only applies if combination medication contains an opioid and/or
                  barbiturate)

               3. Nonsteroidal Anti-inflammatory Drugs or other simple medications ˃ 14 days a
                  month during the 90 days prior to screening

               4. Triptans or ergots ≥ 10 days a month during the 90 days prior to screening

          3. Treated with onabotulinumtoxinA (Botox®) or other botulinum toxin treatment within 4
             months prior to screening for migraine prophylaxis (patients who were treated with
             same for cosmetic purposes may be allowed on a case-by-case basis after approval from
             the Medical Monitor)

          4. A history of or current neurological or psychiatric impairment, or cognitive
             dysfunction that, in the opinion of the Investigator, would compromise data collection

          5. Use of antipsychotics at least 15 days prior to randomization

          6. Patients who received treatment with an investigational drug or device within 30 days
             prior to randomization, or within 3 months if associated with central nervous system

          7. Patients who participated in a central nervous system clinical trial within 3 months
             prior to randomization

          8. Patients who test positive for human immunodeficiency virus (HIV), hepatitis B surface
             antigen (HBsAg), or hepatitis C virus (HCV) antibody serology testing

          9. Patients who are employees or immediate relatives of the employees of the Sponsor, any
             of its affiliates or partners, or of the clinical study research site
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Site 30</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 11</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 31</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 18</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 02</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 29</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 25</name>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <zip>14221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 33</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 28</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2016</study_first_submitted>
  <study_first_submitted_qc>August 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2016</study_first_posted>
  <disposition_first_submitted>March 18, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>March 18, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 20, 2018</disposition_first_posted>
  <last_update_submitted>March 18, 2018</last_update_submitted>
  <last_update_submitted_qc>March 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Headache</mesh_term>
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

